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1. Introduction  
Parkinson’s disease (PD) is a neurodegenerative disorder affecting a variety of brain 
structures. Its prevalence in the general population is around 0.3% and increases 
considerably with age (de Lau & Breteler, 2006). The median age of onset is 60 years and the 
incidence is equal in both sexes (Katzenschlager et al., 2008). While initially symptoms are 
subtle severe disability often requiring permanent care is present in many patients within a 
time-frame of about ten years. On the other hand, there are patients who do not show 
relevant progression of PD over up to ten years (Hoehn & Yahr, 1967). Indeed, the most 
severe state of PD with regard to the Hoehn and Yahr (H&Y) scale may be reached after 6 to 
40 years according to a variety of epidemiological studies (Poewe, 2006). Yet, overall the 
mortality rate of patients with PD is increased by a factor of 1.5-2.5 compared to the general 
population (Poewe, 2006).  
The existence of at least two of the criteria resting tremor, bradykinesia and rigidity in an 
asymmetrical distribution leads the way to the diagnosis of this movement disorder. 
Accordingly, the pentamerous unified Parkinson’s disease rating scale (UPDRS) mainly 
reflects the state of the motor symptoms of PD. Only the first item of the UPDRS takes into 
account psychiatric symptoms of the disease. However, cognitive decline as well as 
psychiatric disturbances are common in patients with PD and pose major problems. While 
the non-motor aspects of PD have been less well studied for a long time, they have received 
more attention in recent years. Nevertheless, therapy of these symptoms is less advanced 
compared to the numerous therapeutic options for the motor symptoms of PD. And not 
infrequently, treatment of motor symptoms and treatment of psychiatric and cognitive 
aspects of PD interfere with each other. For this chapter the literature on some factors of 
non-motor aspects of PD has been reviewed and is summarized here. 
2. Cognitive and psychiatric comorbidities of Parkinson’s disease 
2.1 Dementia in PD 
Epidemiology: Parkinson’s disease is the second most common neurodegenerative disease 
and dementia is one of the main manifestations of PD. A large epidemiological study of 1449 
patients with PD conducted in Germany found a point prevalence of dementia of 28.6% in 
this population (Von Reichmann et al., 2010). Accordingly, meta-analyses of prevalence 
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studies on Parkinson’s disease dementia (PDD) report point prevalence rates of 24.5% 
(Aarsland et al., 2005) or 30% (Marder, 2010). Hence, 30% may be an accurate estimate of the 
point prevalence of PDD. Additionally, it affects probably more than 50% of patients with 
PD in the course of the disease and cumulative prevalence rates reach 80% in some studies 
(Aarsland & Kurz, 2010). Indeed, compared to a control population the risk of developing 
dementia in PD is increased 6-fold (Buter et al., 2008). On the other hand, 3-4% of dementias 
in general are attributed to PD (Marder, 2010).  
The most significant risk factors for developing PDD are a higher age of onset of PD as well 
as a higher degree of severity of parkinsonism. Also, the development of PDD often is 
preceded by the diagnosis of mild cognitive impairment (MCI). It has been suggested that 
deficits in semantic fluency and visuoconstruction indicate a higher risk for developing PDD 
compared to frontal executive dysfunctions (Aarsland & Kurz, 2010). An association 
between dementia and visual hallucinations in PD is established as well. 
Pathophysiology: The pathophysiological mechanisms of PDD are not fully understood. 
As opposed to the motor symptoms cognitive deficits in PD normally do not improve 
with dopaminergic therapy. Therefore other pathology than the cerebral dopamine 
deficit is relevant in the pathophysiology of PDD. Postmortal analysis of brain of patients 
who had clinical symptoms of PDD shows a heterogeneous histological and 
immunochemical profile. Abundant cortical and nuclear Lewy bodies resembling the 
histopathological profile of Lewy body dementia (LBD) may be present. On the other 
hand, the pattern of post-mortem analysis may resemble that of Alzheimer’s disease 
(AD). Lack of cortical amyloid, tau, or synuclein pathology in the presence of Lewy 
bodies in the substantia nigra was associated with less significant dementia underlining 
the importance of cortical pathology regarding PDD (Galvin et al., 2006). More 
knowledge on biomarkers of dementia has evolved in the last years with several studies 
that demonstrated specific findings in the cerebrospinal fluid of patients with PDD 
(CSF). Amyloid-beta (Aβ) peptides are the main components of amyloid-plaques which 
are found abundantly in patients with AD but also form part of the pathological changes 
in the brains of patients with PDD. Presence of the most prominent form of amyloid-beta 
- the Aβ-42 - in the CSF has been shown to be a reliable marker for dementias and 
particularly for AD. But discrimination between AD and PDD or LBD is not possible 
with this marker. However, the ratio between the subforms 42 and 37 of the Aβ protein 
have been proposed as biomarker for a differentiation between AD from PDD and LBD 
whereas the latter two forms of dementia may be differentiable by new subforms of the 
Aβ-protein that have been found in the CSF of patients with dementia (Bibl et al., 2006). 
Other proteins that can be detected in the CSF and whose concentration may indicate 
dementia are phospho-tau and alpha-synuclein. Regarding neurophysiological 
techniques a study analyzing the EEG of 50 patients with AD, 50 patients with LBD and 
40 patients with PDD showed that patients with PDD or LBD had significantly slower 
posterior rhythms (5.6-7.9 Hertz) than patients with AD even in early stages of the 
disease (Bonanni et al., 2008). Neuroimaging studies demonstrate whole brain atrophy in 
PDD lacking confirmed specific changes that would differentiate between patients with 
PD and those with PDD. The co-occurrence of visual hallucinations and PDD has 
prompted pathoanatomical explanations relating both symptoms to Lewy body 
pathology in the temporal lobes (Harding et al., 2002). Another common mechanism of 
these manifestations of PD may be a cholinergic deficit supported by the therapeutic 
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success that can be achieved by application of inhibitors of the acetylcholinesterase 
(Emre et al., 2004). A relation to the known protective effect of cigarette smoking on the 
incidence of PD may exist (Alves et al., 2004). Association of PDD with particular familial 
forms of PD have been demonstrated. But genetic risk factors for PDD exceeding these 
relatively rare forms of PD have not yet been found. 
Phenomenology: Typically, patients with PDD exhibit deficits in different aspects of 
memory. A recent study showed that impaired attentional filtering as well as a reduced 
storage capacity is present in patients with PD even in the absence of dementia (Lee et al., 
2010). However, no specific pattern of cognitive decline is characteristic for PDD and all 
major cognitive domains including memory, attention, constructional function, visuospatial 
function and execution are affected. Differentiation from AD and especially LBD is not 
reliably available based on the neuropsychological testing. Still, many studies suggest 
executive dysfunction as the predominating cognitive pattern in patients with PDD (Emre et 
al., 2007). Importantly, patients with dementia and PD show similar clinical signs compared 
to LBD even though postural instability is more common in PDD. Nevertheless, the 
frequency of falls does not differ between patients with PDD, LBD and AD. Visual and 
auditory hallucinations, as well as depression, sleep disturbances and cognitive fluctuation 
characterize PDD as well as LBD. Importantly, aside from the presence of extrapyramidal 
motor symptoms these criteria common in PDD and LBD are very useful in distinguishing 
PDD from AD (Galvin et al., 2006). The most significant predictor of developing PDD 
compared to patients with PD without dementia are visual hallucinations the occurrence of 
which at any point in the progress of PD increases the risk for developing dementia by a 
factor of twenty (Galvin et al., 2006). Typical clinical features that establish the diagnosis of 
PDD are found in table 1. 
Diagnosis: Recently, a task force of 23 experts in the field of PD developed clinical 
diagnostic criteria for PDD. Features of this disorder were defined as well as the likelihood 
of its diagnosis based on the combination of symptoms (Emre et al., 2007; Goetz et al., 2008). 
According to the criteria in table 1 and 2 diagnosis of PDD is probable if 1) both core 
features are present, 2) at least two cognitive features and at least one behavioral feature are 
present, 3) none of the group III or group IV features are found. Diagnosis of PDD is 
possible if 1) both core features are present, 2) there is an atypical profile of cognitive 
impairment in one or more of the cognitive features like prominent or receptive-type 
aphasia, pure storage-failure type amnesia with preserved attention while behavioral 
symptoms may or may not be present. Possible PDD can be diagnosed also with one or 
more features of category II present in the absence of category IV features (Emre et al., 2007; 
Goetz et al., 2008). 
Therapy: Currently, there are four relevant drugs with approval for the treatment of the 
symptoms of dementias. Donepezil, rivastigmine and galantamine are inhibitors of the 
acetylcholinesterase whereas memantine is an antagonist of the glutamatergic N-methyl-d-
aspartate (NMDA)-receptor. These drugs are approved for the treatment of AD in the 
United States and/or within the European Union. Their indication for treatment of PDD has 
been established or is currently under approval. 20 studies regarding the treatment of PDD 
with inhibitors of the acetylcholinesterase were identified by a review published in 2010. 
The effects of donepezil were investigated in 12 studies, those of rivastigmine in 6 and 
galantamine was tested in 2 studies. 11 of these studies were open-label studies and 2 
reported case series and all of these smaller studies with less than 40 patients showed  
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I. Core features 
 
1. Diagnosis of Parkinson’s disease 
according to Queen Square Brain 
Bank criteria 
 
2. A dementia syndrome with 
insidious onset and slow progression, 
developing within the context of 
established Parkinson’s disease and 
diagnosed by history, clinical, and 
mental examination, defined as: 
1. Impairment in more than one 
cognitive domain 
2. Representing a decline from 
premorbid level 
3. Deficits severe enough to impair 
daily life (social, occupational, or 
personal care), independent of 
the impairment ascribable to 
motor or autonomic symptoms 
II. Associated 
clinical features 
 
1. Cognitive features 
Attention: 
Impairment in spontaneous and 
focused attention, poor performance 
in attentional tasks; performance may 
fluctuate during the day and from 
day to day 
Executive functions:  
Impairment in tasks requiring 
initiation, planning, concept 
formation, rule finding, set shifting or 
set maintenance; impaired mental 
speed (bradyphrenia) 
Visuo-spatial functions:  
Impairment in tasks requiring visual-
spatial orientation, perception, or 
construction 
Memory: 
Impairment in free recall of recent 
events or in tasks requiring learning 
new material, memory usually 
improves with cueing, recognition is 
usually better than free recall 
Language:  
Core functions largely preserved. 
Word finding difficulties and 
impaired comprehension of complex 
sentences 
may be present 
2. Behavioral features 
Apathy:  
Decreased spontaneity; loss of 
motivation, interest, and effortful 
behavior 
Personality: 
Changes in personality and mood 
including depressive features and 
anxiety 
Hallucinations:  
Mostly visual, usually complex, 
formed visions of people, animals or 
objects 
Delusions:  
Usually paranoid, such as infidelity, 
or phantom boarder (unwelcome 
guests living in the home) delusions 
Excessive daytime sleepiness 
Table 1. Features favoring the diagnosis of dementia associated with Parkinson’s disease 
(according to Emre et al., 2007 and Goetz et al., 2008) 
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III. Features 
which do not 
exclude PD-D, 
but make the 
diagnosis 
uncertain 
• Co-existence of any other 
abnormality which may by 
itself cause cognitive 
impairment, but judged not to 
be the cause of dementia, e.g. 
presence of relevant vascular 
disease in imaging 
• Time interval between the 
development of motor and 
cognitive symptoms not 
known 
IV. Features 
suggesting 
other 
conditions or 
diseases as 
cause of mental 
impairment, 
which, when 
present make it 
impossible to 
reliably 
diagnose PD-D 
• Cognitive and behavioral 
symptoms appearing solely in 
the context of other conditions 
such as: 
Acute confusion due to 
- Systemic diseases or 
abnormalities 
- Drug intoxication 
Major Depression according to 
DSM IV 
• Features compatible with 
“Probable Vascular dementia” 
criteria according to NINDS-
AIREN = dementia in the 
context of cerebrovascular 
disease as indicated by  
1. focal signs in neurological 
exam such as hemiparesis, 
sensory deficits, and  
2. evidence of relevant 
cerebrovascular disease by 
brain imaging  
AND  
a relationship between the two as 
indicated by the presence of one or 
more of the following: 
1. onset of dementia within 3 
months after a recognized 
stroke 
2. abrupt deterioration in 
cognitive functions 
3. fluctuating, stepwise 
progression of cognitive 
deficits 
Table 2. Features not favoring the diagnosis of dementia associated with Parkinson’s disease 
(according to Emre et al., 2007 and Goetz et al., 2008) 
improvement in selected clinical outcome measures to some degree. Nevertheless, by nature 
the limitations of these studies’ designs affect their representative value. Still, it may be an 
important clinical observation that improvement of hallucinations was observed among 
patients treated with rivastigmine, donepezil or galantamine in several of these studies 
while their were generally no changes in motor symptoms. 5 of the studies as of 2010 were 
randomized controlled trials of which only two had included more than 40 patients (van 
Laar et al., 2010). One of these studies investigated the effects of rivastigmine while the other 
investigated the effects of donepezil in patients with PDD. The latter study has not been 
published in a peer-reviewed journal as of April 2011 and results of the review are based on 
a poster presentation at an international conference in 2007 (van Laar et al., 2010). According 
to this preliminary review, this study included 550 patient with PDD who were randomized 
to one of three treatment arms receiving either 5 mg donepezil, 10 mg donepezil or placebo. 
A trend towards improvement but no significant effect on the primary cognitive outcome 
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scales was the main result of this report. Nonetheless, significant improvement was present 
in several secondary outcome measures like the mini-mental state examination (MMSE), the 
brief test of attention (BTA) or the verbal fluency test from the Delis-Kaplan executive 
function system test battery (D-KEFS). Nausea and parkinsonian side effects were reported 
as most common adverse events. In the other placebo-controlled, randomized trial with 541 
patients a moderate effect of 3-12 mg rivastigmine per day on cognitive outcome measures 
in patients with PD and mild to moderate dementia has been demonstrated. Primary 
efficacy variables were the scores for the cognitive part of the Alzheimer’s disease 
assessment scale (ADAS-cog) and the scores for the Alzheimer’s disease cooperative study-
clinician’s global impression of change (ADCS-CGIC) which both showed improvement in 
the group of patients treated with rivastigmine compared to the placebo-group. 
Importantly, both scales which originally are derived from use in patients with AD are 
regarded as valid and reliable for use in patients with PDD as well (Harvey et al., 2010). A 
decrease of 2.1 points in the ADAS-cog was found in the verum group while the score of this 
scale increased by 0.7 after 24 weeks of application of the placebo. This decline in cognitive 
performance has been attributed to the natural course of PDD. Significant but only weak 
improvement was found in several other scales of cognitive performance and activity level. 
The rate of side-effects like nausea (29%), vomiting (16.6%), tremor (10.2%) and dizziness 
(5.8%) was significantly increased in patients who had received rivastigmine compared to 
those who had received placebo leading to a drop out rate due to adverse effects of 17% in 
the treated group compared to 8% in the placebo group (Emre et al., 2004). In line with the 
cited observations of previous reports and open studies the rate of hallucinations in the 
group receiving rivastigmine was significantly lower than in the placebo group. In fact, 
presence of hallucinations tended to be a predictor of favorable cognitive outcome. An open-
label extension study with a daily dose of 3-12 mg rivastigmine for another 24 weeks in 334 
patients with PDD who previously had received rivastigmine or placebo largely confirmed 
the results of the original study. Hence, the efficacy as well as the profile of side effects of 
rivastigmine were reproduced in the group that had received placebo during the first part of 
the study (Poewe et al., 2005). Additionally, in a large meta-analysis on therapy of dementia 
in patients with PD it was concluded that rivastigmine could improve cognition and 
activities of daily living (Maidment et al., 2006). Memantine has been tested in several 
clinical trials in patients with PDD. In a first pilot study of this drug in PDD there was no 
beneficial effect on cognitive outcome measures while a good tolerability compared to 
application of inhibitors of the acetylcholinesterase was shown (Leroi et al., 2009). An early 
double-blind placebo controlled trial showed a positive effect in the clinical global 
impression of change scale as well as an improved speed on attentional tasks under 
treatment with memantine (Aarsland et al., 2009). But more recent evidence from a 
randomized, double-blind, placebo-controlled trial with 199 participants with PDD or LBD 
showed no clinical benefit in patients with PDD in any of the cognitive tests applied after 24 
weeks of therapy whereas those with LBD improved moderately (Emre et al., 2010). 
Therefore, memantine may not be regarded as choice for the pharmacotherapy of PDD. Use 
of galantamine has been tested in one clinical trial which reported overall beneficial effects 
on several scales of cognitive performance as well as improvement of hallucinations, 
anxiety, apathy and sleep disturbances (Litvinenko et al., 2008). However, this was an open 
controlled trial. Still, not unlike in other forms of dementia the current therapeutic options to 
treat PD dementia are purely symptomatic. And unfortunately, the effect size of 
antidementive drugs tends to be small in the therapy of dementias may they be related to 
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PD or not. Finally it can be concluded that rivastigmine is currently the only FDA-approved 
drug to treat dementia associated with PD while donepezil can be considered as a treatment 
choice. When applying rivastigmine in patients with PDD slow titration should be adhered 
to in order to reduce the incidence of side effects like tremor or nausea. A transdermal patch 
of rivastigmine now available for treatment has been shown to be more tolerable compared 
to the capsule applied normally (Winbald et al., 2007). This may enable more frequent use 
and use of higher doses of rivastigmine in patients sensitive to side-effects of this drug. 
Whether rivastigmine or other inhibitors of the acetylcholinesterase is applicable for the 
primary treatment of hallucinations may be subject of future studies.  
2.2 Depression in PD 
Epidemiology: Depression is one of the most common diseases of humans and up to 21 
million people in Europe are affected by uni- or bipolar depression (Olesen et al., 2006). In 
the western world it is among the most common causes of incapacity to work among 
employees under the age of 50 years. Depression may also be the most common psychiatric 
comorbidity in patients with PD. Reported prevalence rates of depression in PD vary 
between 3 and 90% depending on the population studied. Whereas earlier reports suggested 
prevalence rates of 40-50% (Zesiewicz & Hauser, 2002) more recent studies tend to report a 
lower prevalence of moderate to severe depression of 5-20% (Tandberg et al., 1996; Schrag et 
al., 2001). In fact, these figures are in line with a recent meta-analysis which calculated an 
average prevalence of depression in PD of 17%. Regarding prevalence rates the population 
under investigation needs to be exactly defined. In exemplum prevalence rates tend to be 
smaller in population studies as compared to inpatient or outpatient cohorts (Reijnders et 
al., 2008). Minor depression was found in 22% of the patients within this meta-analysis. 
Finally, a recent large nationwide study in Germany with 315 participating neurological 
settings recruited a random sample of 1,449 outpatients with PD who performed a 
standardized clinical assessment in order to evaluate the frequency of dementia, depression, 
and other neuropsychiatric symptoms in PD on a selected study day. Depression as defined 
by a score of ≥14 in the Montgomery Asberg depression rating scale (MADRS) was 
diagnosed in 23.8% of all patients. Though not directly related to age prevalence of 
depression increased from 14.7% in patients with PD in HY stage I-II to 44.9% in patients 
with HY status IV-V (Riedel et al., 2010). Given that there are about 1.2 million patients 
suffering from PD in Europe 250.000 to 600.000 of these patients may be affected by any type 
of depression.  
Pathophysiology: The major mechanism that underlies the antidepressant effect of most 
antidepressant drugs is an increase of the concentration of neurotransmitters in the synaptic 
cleft by inhibition of axonal reuptake mechanisms or inhibition of intrasynaptic 
fermentation. The most relevant neurotransmitters targeted by antidepressants are the 
monoamines dopamine, noradrenaline and serotonine. The discovery of the mechanisms of 
action of these antidepressants has considerably influenced the pathophysiologic theory of 
transmitter deficiency in depression still valid today (Kalia, 2005; Schildkraut, 1965). 
However, as opposed to the pathophysiologic models of PD there is no specific 
neuropathoanatomical correlate for depression. Several systems of transmitters and cortical 
areas are thought to be altered in patients with depression. Hypometabolism in a FDG-PET 
has been demonstrated in the dorsal and ventral prefrontal cortex, as well as in the anterior 
cingulate cortex and the inferior parietal region in patients with depression (Mayberg, 2002). 
Increased cerebral blood-flow was found in the orbital cortex, the medial thalamus and the 
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amygdala (Drevets, 2000). Studies with post-mortal cerebral tissue of patients who had 
suffered from depression indeed have shown cell atrophy in the dorsolateral prefrontal 
cortex and the orbitofrontal cortex as well as cell loss in the subgenual prefrontal cortex 
(Rajkowska, 2000). Other studies report on hippocampal volume loss in patients with major 
depression being related to the duration of the disease suggesting a possible link between 
the pathophysiology of neurodegenerative disorders and depression (Bremner et al., 2000). 
Cell loss or cell atrophy in depressed patients have been partially attributed to elevated 
cellular “stress” particularly mediated by corticosteroids. Reduced neuronal plasticity 
substantiated by decreased levels of the brain derived neurotrophic factor (BDNF) which 
plays an important for neuronal plasticity has been suggested to be causative for neuronal 
cell atrophy or cell loss. Interestingly, antidepressant treatment was found to upregulate the 
neuronal expression of the BDNF among others. Therefore, a neuroprotective effect of 
antidepressants on neuroanatomical structures which are affected by depression has been 
proposed (Duman et al., 2000). Regarding another neurotransmitter system, loss in cortical 
cholinergic function has been shown in a PET-study in patients with PD dementia and 
depression (Bohnen et al., 2007). Also  there is a degeneration of several subcortical nuclei in 
PD a finding that resembles results from patients with depression only (Lisanby et al., 1993). 
Twin studies indicate hereditarity of major depression of 30-40 %. Still, there is no single 
genetic locus with a high association to depression whereas several polymorphisms of 
serotonine-transport genes or genes of the mono-amino-oxidase (MAO) have been linked to 
depression. Generally, depression is regarded as a polygenetic disease (Ebmaier et al., 2006; 
Hamet & Tremblay, 2005). These mechanisms have been recognized in the pathogenesis of 
major depression in the absence of PD but probably represent the most relevant mechanisms 
that lead to depression in patients with PD as well (Lemke et al., 2004). 
Phenomenology: Not unlike other patients with depression patients with PD and 
depression present loss of interests, depressed mood, anhedonia, hopelessness, pessimism, 
feeling of worthlessness, loss of weight, insomnia, less often hypersomnia, suicidal ideas. 
Symptoms like hypomimia, bradyphrenia, disturbance of libido or sleep which are common 
in depression are common symptoms of PD without coexisting depression as well and may 
pose problems regarding their differentiation. Importantly, depression is thought to precede 
the occurrence of motor symptoms in PD not infrequently.  
Apathy has been proposed as a symptom or syndrome distinct from depression in PD. 
Apathy is a condition which is characterized by a primary lack of motivation and involves 
behavioral, cognitive and affective deficits while there is no relevant affective component i.e. 
no feelings of sadness, depressed mood or feelings of worthlessness. Problems with the 
initiation and sustaining of activities have been described as being characteristic for apathy 
(Pluck & Brown, 2002). Even though symptoms of apathy and depression overlap apathy 
can occur in the absence of depression as has been demonstrated particularly in patients 
with progressive supranuclear palsy (PSP) (Litvan et al., 1996). 
Diagnosis: The most common diagnostic manuals which define criteria for diagnosing a 
major depressive episode are the diagnostic and statistical manual of mental disorders 
(DSM-IV) as well as the tenth edition of the classification of diseases and related health 
problems  (ICD-10). In the DSM-IV five or more of nine defined depressive symptoms of 
which one has to be either depressed mood or loss of interest/pleasure have to be present 
for at least 2 weeks and must represent a change from previous states. Besides 1) 
depressed mood most of the day (indicated by feeling or expression of sadness) and 2) 
reduced interest or pleasure in activities the other predefined symptoms which should 
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each be present nearly every day are 3) significant weight loss or weight gain (change 
>5% of the body weight within one month), 4) insomnia or hypersomnia most of the day, 
5) psychomotoric retardation or agitation, 6) fatigue/loss of energy, 7) the feeling of 
worthlessness or inappropriate guilt, 8) reduced concentration or ability to think, 9) 
recurrent thoughts of death/suicidal ideation/a plan for committing suicide or a suicide 
attempt. Significant clinical distress and impairment in the absence of a recognized 
medical condition accounting for the depressive symptoms are further criteria that need 
to be checked in order to diagnose a major depressive episode (American Psychiatric 
Association, 2010a). In the ICD-10 the depressive episodes can be categorized into mild, 
moderate or severe forms. While using a catalogue of criteria comparable with that of the 
DSM-IV diagnosis of a mild depressive episode requires 2 to 3 of the criteria, while a 
moderate depressive episode is diagnosed when 4 or more criteria are fulfilled. In contrast 
to a moderate depressive episode, presence of suicidal thoughts or plans as well as 
presence of several somatic symptoms indicate a severe depressive episode (World Health 
Organization, 2007a). Depressions often are classified based on depression scales like the 
Hamilton depression scale (HAM-DS) or Beck’s depression inventory or the Montgomery 
Asberg depression rating scale (Gotham et al., 1986). These scales differ regarding the 
significance of somatic and psychic symptoms and the HAM-DS is probably the most 
frequently used inventory in patients with PD and depression (Dissanayaka et al., 2007; 
Schrag et al., 2007).  
Therapy: Despite the existence of a broad spectrum of antidepressants there is scarce 
evidence for the efficacy of antidepressants in patients with PD. Studies utilizing selective 
serotonin reuptake inhibitors (SSRIs) like citalopram, sertraline and paroxetine or tricyclic 
antidepressants imipramine, desipramine, amitriptyline and nortriptyline or bupropion 
have been conducted. In a large literature review effect sizes between antidepressant and 
placebo treatment did not differ in patients with PD and depression being in line with 
previous meta-analyses (Weintraub et al., 2005). Within this review only 11 studies 
performed between 1965 and 2003 with a treatment duration of about 12 weeks on average 
utilizing SSRIs in the majority were found suitable for meta-analysis. Only two of these 
studies were placebo-controlled trials. Sample size was 30 patients on average. Generally, 
the effect size of antidepressant as well as placebo treatment was regarded as considerable. 
Therefore, nonspecific treatment effects were suggested as likely reason for the positive 
effects reported in several open-label studies. In accordance, the effect size found was 
similar to that of placebo arms of randomized, placebo-controlled trials in elderly patients 
with depression and without PD. Finally, the completion rates of open-label studies with 
antidepressants were about 87% in general and 86% in patients receiving SSRIs thus 
deeming poor tolerance of antidepressants in patients with PD an unlikely cause of the 
ineffective antidepressive action (Weintraub et al., 2005). In the meantime two rather small 
placebo controlled trials with each about 50 participants have demonstrated superiority of 
selected antidepressants. In one study citalopram as well as desipramine proofed to be more 
affective than placebo 30 days after initializing treatment as demonstrated by significant 
improvement in the Montgomery Asberg depression rating scale (MADRS). Additionally, 
treatment with desipramine resulted in a significant antidepressant effect after 14 days as 
well. On the other hand, side-effects were reported twice as often in patients with 
desipramine compared to patients who received citalopram being often in accordance with 
the anticholinergic profile of tricyclic drugs. Still, with 15 or less patients in each group 
sample sizes were low (Devos et al., 2008). In another recent placebo controlled trial 
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application of 48.5 mg of nortriptyline on average and 28.4 mg of paroxetine on average 
each was compared to placebo in 52 patients with PD and depression. The primary outcome 
variable in this study was change in the Hamilton depression rating scale (HAM-D). While 
nortriptyline was superior to placebo 2 and 8 weeks after initializing treatment paroxetine 
was not. Also the responder rate defined as a change of ≥50% in the HAM-D was 
significantly higher in the group treated with nortriptyline (Menza et al., 2009). Other 
studies have evaluated the antidepressant effect of antiparkinsonian medication. Most 
recently it has been shown that depressive symptoms in PD can be treated with the 
dopamine agonist pramipexole (Barone et al., 2010). Of 287 patients with mild to moderate 
PD on stable antiparkinsonian therapy 139 received 0.125 – 1.0 mg pramipexole three times 
a day and 148 received placebo each over 12 weeks. Significant therapeutic effects of 
pramipexole on Beck’s depression inventory as well as in the UPDRS motor scores were 
found. Therefore, pramipexole may be a favorable primary choice for patients with PD and 
depression. 
2.3 Psychoses in PD 
Epidemiology: Hallucinations, illusions and delusions are the main psychotic symptoms in 
PD. Among these hallucinations are the most common with visual hallucinations being 
much more frequent than acoustic hallucinations. Tactile hallucinations are less frequent 
and prevalence rates are not well-established. Olfactory hallucinations should be regarded 
as unusual in PD and there are occasional reports on this type of phenomenon. 
Hallucinations occur in up to 40% of patients with PD if minor visual hallucinations like 
sensation of the presence of another person are included (Fénelon et al., 2000). Within the 
parkinsonian disorders visual hallucinations occur predominantly in PD and dementia with 
Lewy bodies. They are much less likely to occur in patients with progressive supranuclear 
palsy (PSP), multiple system atrophy (MSA) or vascular Parkinsonism and in fact this 
symptom has been proposed as a useful predictor for the differential diagnosis of these 
groups of parkinsonian syndromes (Williams et al., 2008).  
Pathophysiology: In a post-mortem study of 788 brains of patients with history of 
parkinsonism a history of visual hallucinations predicted the existence of Lewy body 
pathology with 93%. On the other hand visual hallucinations were present in 50% of 
patients with PD and 73% of patients with LBD (Williams et al., 2008). Visual hallucinations 
were identified as a symptom of advanced stages of Lewy body parkinsonism and occurred 
in the second half of the duration of PD from onset to death in almost every patient in this 
study. In a longitudinal study with 5-year clinical follow up patients were divided into two 
groups: those who experienced hallucinations within 3 months after initiating levodopa 
therapy and those who experienced such hallucinations after 1 year or later. In everyone of 
the 12 patients who had experienced hallucinations during the first 3 months of levodopa 
treatment the primarily made diagnosis of PD had to be revised either due to a newly 
diagnosed underlying psychiatric illness or due to existence of LBD or AD with 
extrapyramidal signs (Goetz et al., 1998a). Therefore, very early occurrence of hallucinations 
should prompt a control of a diagnosis of PD. With regard to the dopamine hypothesis of 
schizophrenia and the fact that antipsychotic drugs all include an antidopaminergic effect it 
may be reasoned that the occurrence of psychosis in PD is due to the dopaminergic 
treatment. Indeed, it has been suggested that treatment with levodopa may “kindle” 
psychotic symptoms in PD (Moskovitz et al., 1978). Still, other diseases which are treated 
with dopaminergic agents like hyperprolactinemia do not carry an increased risk for 
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hallucinations (Williams & Lees, 2005). Additionally, intravenous infusion of levodopa was 
not able to induce hallucinations in patients who experienced spontaneous hallucinations on 
a daily basis rendering a simple association of hallucinations to levodopa serum-levels 
unlikely (Goetz et al., 1998b). And importantly, hallucinations have been described in 
patients with PD before introduction of levodopa into therapy of PD (Diederich et al., 2009). 
Probably, the pathophysiology of PD itself is mainly responsible for the increased risk of 
hallucinations in patients with PD. Similarly, other neurodegenerative disorders like AD or 
LBD harbor a higher risk for the occurrence of hallucinations in the absence of dopaminergic 
treatments. Additionally, there appears to be a difference between the levodopa-equivalent 
dose between patients with hallucinations and those without hallucinations (Diederich et al., 
2009). Pathophysiologically, the existence of Lewy bodies in the basolateral nucleus of the 
amygdala as well as in the parahippocampus and other inferior temporal regions has been 
identified as possible correlate of visual hallucinations (Harding et al., 2002). A correlation 
between cholinergic dysfunction and visual hallucinations has been recently established 
when the short-latency afferent inhibition - a neurophysiologic measure of inhibitory 
intracortical mechanisms depending on cholinergic function - was shown to be significantly 
reduced compared to patients with PD and compared to healthy controls without visual 
hallucinations (Manganelli et al., 2009). 
Phenomenology: In accordance with previous statements early presence of visual 
hallucinations is a predictor for early mortality (Williams & Lees, 2005). Additionally, there 
is a correlation between visual hallucinations and cognitive dysfunction which may reflect 
its association with advanced disease state. Nevertheless, cognitive function of patients 
without visual hallucinations appears not to differ from those with minor hallucinations 
whereas patients with major visual hallucinations show deficits in verbal fluency tasks 
which are not found in patients without visual hallucinations (Llebaria et al., 2010).  
In one study with 216 patients hallucinations were divided into three groups. First, 
minor forms of hallucinations including the feeling of the presence of somebody or 
something, which was also the most frequent hallucination, were grouped together. With 
regard to this type of hallucination, patients perceived the presence of a living or 
deceased relative, another person, an animal or an unidentified sensation. Within the 
group of the minor symptoms hallucinations of passage were identified as distinctive 
phenomena and were described as a brief impression of a person or animal (frequently a 
cat or a dog) passing by. Illusions were a second group of symptoms and were described 
as impression of a transformation of an object e.g. into an animal (Fénelon et al., 2000). 
Formed visual hallucinations and auditory hallucinations formed the other major groups 
of hallucinations in PD in this study. With a prevalence of approximately 10% auditory 
hallucinations in PD are less common than visual hallucinations and frequently do not 
occur alone but in association with visual hallucinations (Inzelberg et al., 1998; Fénelon 
et al., 2000). Auditory hallucinations are perceived as externally generated human voices. 
They may be incomprehensible or may be commenting familiar voices. In contrast to 
auditory hallucinations in schizophrenia they predominantly do not have an affective 
component, are not imperative and are not paranoid in character in PD (Inzelberg et al., 
1998). Tactile hallucinations have been rarely reported. One study described eight 
patients with PD and tactile hallucinations which were always associated with 
simultaneously or non-simultaneously occurring visual or auditory hallucinations. Those 
tactile hallucinations predominantly included the sensation of contact with animals like 
spiders, cockroaches, grubs, mites, ants or rats. Often sensation of contact with these 
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small animals were also subject of simultaneous visual hallucinations. They occurred 
predominantly in the evening or at night and were perceived as unpleasant. Interestingly 
and in accordance with the descriptions of visual hallucinations insight into the non-
realistic nature of the phenomena was maintained or recovered within a few seconds 
(Fénelon et al., 2002). 
Diagnosis: Only 20% percent of patients with PD spontaneously report the occurrence of 
hallucinations or other psychotic symptoms (Fénelon & Alves, 2010). Therefore, these 
symptoms should be actively asked for when examining patients and/or persons associated 
with the patient’s care. There is no generally accepted scale for evaluation of psychotic 
symptoms in PD. An expert group recently suggested criteria for the diagnosis of PD 
associated with psychosis. First, at least one of the symptoms of hallucinations, illusions, 
delusions or false sense of presence has to be present. Second, the primary diagnosis of PD 
has to be established according to the UK Brain Bank criteria for PD. Third, the onset of PD 
has to precede the onset of the psychotic symptoms mentioned first. Fourth, the symptoms 
occur recurrently or continuously for at least one month. Fifth, other possible causes of 
parkinsonism and psychiatric disorders have to be excluded. Sixth, it should be specified if 
symptoms occurred a)with or without insight, b)with or without preexisting dementia and 
c) if they were associated with a specific treatment for PD (Ravina et al., 2007). 
Therapy: Upon occurrence of psychotic symptoms in PD possible reversible causes have to 
be excluded. First, any association to changes of the patients antiparkinsonian treatment has 
to be reviewed. If there is no recent change in medication which could explain the onset of 
psychotic symptoms modification of the patients’ medication should follow a distinct 
sequence which ranks the psychotic potential of different classes of drugs used in the 
treatment of patients with PD. According to the guidelines of the German Neurological 
Association 1) anticholinergic substances and tricyclic antidepressants which carry 
anticholinergic side-effects should be discontinued. 2) budipine, amantadine and inhibitors 
of the mono-amino-oxidase-B (MAO-B) should be reduced or discontinued, 3) dopamine-
agonists should be reduced or discontinued, 4) inhibitors of the catechyl-O-methyl-
transferase (COMT) should be reduced or discontinued, 5) therapy with levodopa may be 
reduced to its lowest effective dose if reduction/discontinuation of one or more of the 
previously listed substances did not to lead to relief from psychotic symptoms (Eggert et al., 
2008). Secondary, a relation to the treatment with other drugs e.g. antibiotics that can 
increase the likelihood of psychotic symptoms should be assessed. Third, acute infection or 
imbalance of serum electrolytes should be excluded. Restitution of the dopaminergic deficit 
caused by cell loss of the neurons of the pars compacta of the substantia nigra is the leading 
mechanisms of most antiparkinsonian drugs. On the other hand antipsychotic drugs all act 
antidopaminergic based on the dopamine-hypothesis of psychosis. Most of the classic 
antipsychotic drugs especially of the butyrophenon group exhibit a high affinity to several 
D (=dopamine)-receptors especially the D2-receptors. Therefore most antipsychotic drugs 
can not be used in PD. However, for therapy of psychosis or hallucinations in PD the group 
of atypical antipsychotics is much better tolerated from patients with PD due to a more 
favorable mechanism of action. A fast dissociation of atypical neuroleptics from the D2-
receptor has been proposed as possible explanation for the comparatively good tolerability 
in patients with PD therefore being first-line therapeutics in Parkinson patients with 
psychotic symptoms (Kapur & Seeman, 2001). Notably, quetiapine or clozapine are the 
preferred antipsychotic drugs in patients with PD. Clozapine is the drug of choice for the 
treatment of psychosis in patients with PD and is used in a low-dose range of 25-100 mg/d. 
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It acts predominantly on the D4-dopaminergic receptor and therefore has less impact on the 
striatonigral dopaminergic system which exhibits predominantly D1- and D2-receptors. 
Several studies have proven the effectiveness of clozapine in treating psychotic symptoms in 
PD. One rater-blinded study compared quetiapine and clozapine use in 27 patients with PD 
and psychosis. Both drugs were effective in treating psychosis based on the clinical global 
impression of change scale (CGIC). Whereas clozapine was more efficient in treating 
delusions it induced leucopenia in one case (Merims et al., 2006). Clozapine has proven its 
efficacy in a randomized, double-blind, placebo-controlled trial with 60 patients who 
received either placebo or clozapine in a dose of 50 mg or less for 4 weeks while the 
antiparkinsonian medication was left stable. A significant improvement in all clinical rating 
scales was demonstrated and importantly there was no deterioration of motor symptoms. 
But one case of leucopenia occurred (The Parkinson Study Group, 1999). Side-effects of 
clozapine are sleepiness, dysarthria, weight gain which are dose-dependent and less 
common in patients with PD psychosis as compared to patients with schizophrenia where 
much higher doses of up to 1000 mg per day are used. However, the risk of agranulocytosis 
of clozapine requires regular blood counts and depending on individual legislations the 
patient needs to be carefully instructed regarding benefits and risks and informed consent 
may be obtained before starting a treatment with clozapine. Quetiapine is the second 
atypical antipsychotic used in patients with PD. Its effect is probably mainly mediated by 
antagonistic effects on 5HT2-, D1- and D2-receptors with a higher selectivity for 5HT2-
receptors. Common side effects of quetiapine include sedation, hypotension, increase in 
weight and change of blood sugar and lipids. Moreover, there have been case reports of 
agranulocytosis, prolactin elevation and rhabdomyolysis under therapy with quetiapine 
(Stephani & Trenkwalder, 2010). Whereas the efficacy of clozapine has been proven by 
blinded studies a double-blind study which compared quetiapine use to placebo in patients 
with PD and psychosis over a three-month interval found no significant effect in any clinical 
scale evaluated (Rabey et al., 2006). The number of patients in this study was rather small 
due to a significant drop-out rate which may have influenced the results. Indeed, the result 
of this trial contrasts with the clinical experience which favors a beneficial role of quetiapine 
for treatment of psychosis in PD. And currently the use of quetiapine for the treatment of 
psychotic symptoms in patients with PD is widely accepted despite the inconclusive 
evidence on the topic. It has been proposed that this discrepancy of negative studies and 
positive clinical evaluation may be due to the sedative (side-)effect of quetiapine rather than 
a direct anti-hallucinatory effect (Diederich et al., 2009). Doses of up to 300 mg quetiapine a 
day are currently applied in patients with PD. Aside from pharmacotherapy, patients 
experiencing visual hallucinations naturally often use coping strategies. These have been 
categorized into visual techniques, cognitive techniques and interactive techniques 
(Diederich et al., 2003). Visual techniques include focusing on the hallucination or 
defocusing. With cognitive techniques the patient should try to actively remain conscious 
about the hallucinatory or illusionary nature of the psychotic symptom. Interactive 
techniques would describe any technique that requires participation of others. Patients may 
be asked for application of such techniques and may be instructed on if required. However, 
there are no controlled studies on the effectiveness of this kind of therapeutic approach. 
2.4 Impulse control disorders 
The chapter on mental and behavioral disorders of the 10th revision of the international 
statistical classification of diseases and related health problems (ICD-10) lists 4 specific 
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habit and impulse control disorders which are pathological gambling (F63.0), pyromania 
(F63.1), kleptomania (F63.2) and trichotillomania (F63.3). Whereas pathological gambling 
is a well-known impulse control disorder in patients with PD there is no report of 
pyromania in patients with PD available. Anecdotal reports of kleptomania and 
trichotillomania in PD exist but there is no study on their frequency in patients with PD 
compared to controls. In addition to pathologic gambling there are other specific 
psychiatric disorders that have been found to exist in patients with PD and that are not 
listed in the group of impulse control disorders in the ICD-10 but share characteristics 
with disorders of the impulse control. Hypersexuality is currently neither directly 
classified in the DSM-IV of the American psychiatric association nor in the ICD-10. 
Excessive sexual drive (F52.7) is classified in the latter within the subsection of sexual 
dysfunctions and comprises those deviations classically named satyriasis and 
nymphomania. Similarly, binge-eating can be a impulse control disorder-like psychiatric 
comorbidity in patients with PD. Binge-eating most closely corresponds to the symptom 
of overeating (F50.4) among the non-organic eating disorders classified in the ICD-10. 
Oniomania which is compulsive shopping again is not a specified symptom in the current 
psychiatric classifications and therefore may be ranked within the category of “other 
impulse control disorders” (F63.8) of the ICD-10. These disorders have been also 
described as repetitive and reward-seeking behaviors or behavioral addictions concepts 
that considerably overlap with that of compulsive or impulsive control disorders. These 
disorders are regarded as dopamine replacement related-disorders therefore being 
extrinsically generated and not directly depending on PD itself (Wolters et al., 2008). 
2.4.1 Pathological gambling 
According to the ICD-10 of the World Health Organization (WHO) pathological gambling 
consists of “frequent, repeated episodes of gambling that dominate the patient’s life to the 
detriment of social, occupational, material, and family values and commitments” (World 
Health Organization, 2007b). Pathological gambling was found to have a lifetime prevalence 
of 0.42% in a large US cohort (Petry et al., 2005). In patients with PD this trait was reported 
in more than 7% of those who were on a dopamine agonist (Voon et al., 2006a). The overall 
lifetime prevalence of pathologic gambling in PD has been reported to be 3.4% and the point 
prevalence was reported with 1.7% (Voon et al., 2006b). Similarly, in a prospective study of 
388 consecutive PD clinic patients a prevalence of pathological gambling of 4.4% in general. 
and of 8% in patients treated with dopamine agonists was demonstrated (Grosset et al., 
2006). Pathological gambling as a psychiatric comorbidity of PD can be largely attributed to 
therapy with dopamine agonists or levodopa and has been recognized in patients with 
restless legs syndrome treated with dopamine agonists as well (Pourcher et al., 2010). 
Confirmatory, there is no evidence for an increased prevalence of this trait in untreated 
patients with PD (O’Sullivan & Lees, 2007). A younger age of onset of PD, a higher novelty 
seeking personality profile and an impaired planning capacity each compared to patients 
with PD but without impulse control or compulsive behaviors have been recognized as 
factors associated with the occurrence of pathological gambling in PD. A positive personal 
or immediate family history of alcohol use disorders is a risk factor for developing 
pathological gambling indicating a genetic predisposition (Voon et al., 2007). 
Pathophysiologically, a functional magnetic resonance imaging (fMRI) study with 12 female 
patients with restless legs syndrome without pathological gambling who were under 
chronic therapy with dopamine agonists showed that the ventral striatal activation upon 
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receipt or omission of rewards in a gambling task during dopaminergic treatment differed 
significantly from that while off treatment with dopamine agonists (Abler et al., 2009). The 
diagnosis of pathological gambling currently is often based on the criteria of the DSM-IV. 
These indicate persistent and recurrent maladaptive gambling behavior as indicated by five 
(or more) of the following: the patient 1) “is preoccupied with gambling”, 2) “needs to 
gamble with increasing amounts of money in order to achieve the desired excitement”, 3) 
“has repeated unsuccessful efforts to control, cut back, or stop gambling”, 4) “is restless or 
irritable when attempting to cut down or stop gambling”, 5) “gambles as a way of escaping 
from problems or of relieving a dysphoric mood”, 6) “after losing money gambling, often 
returns another day to get even”, 7) “lies to family members, therapist, or others to conceal 
the extent of involvement with gambling”, 8) “has jeopardized or lost a significant 
relationship, job, or educational or career opportunity because of gambling”, 9) “relies in 
other to provide money to relieve a desperate financial situation caused by gambling”. 
Additionally, a manic episode as possible underlying cause needs to be excluded (American 
Psychiatric Association, 2010b). A history of illegal acts like forgery, fraud theft, 
embezzlement to finance gambling is currently a 10th possible criterion for the diagnosis of 
pathological gambling but is not included in the proposed revision for the DSM-5 which is 
scheduled to be released 2013. Importantly, the work group for this revision also proposes 
to reclassify the diagnosis from an impulse-control disorder into a substance-related 
disorder (American Psychiatric Association, 2010b). The therapy of choice of pathological 
gambling in PD is the discontinuation of the dopamine agonist and replacement by an 
adequate dose of levodopa. In fact, 15 patients with PD and pathological gambling were 
followed up for 21 months on average. In all of them the treatment with dopamine agonists 
had been discontinued and was replaced by levodopa. All of them reported cessation of the 
pathological gambling even though one patient reported to have a continuing urge to 
gamble (Macphee et al., 2009). If levodopa itself is the suspected cause of pathological 
gambling dose reduction will be necessary. 
2.4.2 Hypersexuality 
In a large multicentre study the prevalence of compulsive sexual behavior in patients with 
PD was 3.5% (Weintraub et al., 2010). Others found lifetime prevalence rates of 2.4% in 
patients with PD with a point prevalence of 2.0%. The lifetime prevalence increased to 
7.2% in patients on therapy with dopamine agonist (Voon et al., 2006b). Importantly, 
hypersexuality occurs nearly exclusively in male patients according to most reports. 
However, this symptom has been also recognized in women with PD (Cooper et al., 2009). 
There is a proposal for operational diagnostic criteria of symptoms defining 
hypersexuality. 1) maladaptive preoccupation with sexual thoughts, 2) inappropriately or 
excessively requesting sex from spouse or partner, 3) habitual promiscuity, 4) compulsive 
masturbation, 5) use of telephone sex lines or pornography, 6) paraphilias are symptoms 
that can define hypersexuality if one or more of them persist for at least one month and if 
symptoms are not exclusively due to a period of hypomania or mania. Additionally, this 
must cause at least one of the following 1) marked distress, 2) unsuccessful attempts to 
control thoughts or behavior or marked anxiety or distress due to such attempts, 3) 
significant time consuming 4) interference with social or occupational functioning (Voon 
et al., 2006b). If none of the last 4 symptoms are found while the other symptoms of 
hypersexuality are present subsyndromal hypersexuality may be diagnosed. 
Dopaminergic drugs are a significant risk factor for the occurrence of hypersexuality in 
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PD. They are present in 90% of those patients with PD developing the disorder. 
Additionally, symptoms may resolve as soon as dopamine agonists are discontinued 
while continuing treatment with levodopa. Also association with other obsessive or 
addictive symptoms is frequent (Klos et al., 2005). An association to depression has been 
described and it is not clear whether there is any functional dependency between both 
symptoms. Therapeutically, the medical history of the patients needs to be controlled for 
any temporal relation of the occurrence of pathological gambling to installation of a 
dopamine agonist therapy. If applicable a treatment with such a dopamine agonist should 
be reduced or replaced by an equivalent dose of levodopa. Persisting symptoms may then 
even warrant other therapeutic options like general reduction of the dopaminergic 
treatment. There is no evidence for specific pharmacologic treatments of hypersexuality in 
PD. 
2.4.3 Obsessive eating 
The prevalence of obsessive eating or binge-eating among patients with PD was 1% in a 
recent analysis while subthreshold binge eating was diagnosed in about 8% (Zahodne et al., 
2011). However, in a cross-sectional study with 3000 patients with PD binge eating was 
diagnosed in 5.6% (Antonini & Cilia, 2009). The weight gain often is significant and an 
average gain of 13 ± 7 kg has been found in 7 patients with this disorder (Nirenberg & 
Waters, 2005). As in other impulse control disorders in PD the major risk factor is the use of 
a dopamine agonist of which pramipexole based on the existing literature has been most 
often associated with obsessive eating. Other risk factors  include a young age of onset of 
PD, a personal or direct family history of addictive behavior as well as a novelty seeking 
and impulsive personality profile. A mechanism based on stimulation of the mesolimbic 
dopaminergic reward system which is probably common to the impulse control disorders 
recognized in PD has been proposed as being causative for obsessive eating. Again, 
discontinuation of dopamine agonists is effective based on evidence from case reports 
(Nirenberg & Waters, 2005; Khan & Rana, 2010).  
2.4.4 Oniomania 
This symptom also known as compulsive shopping is characteristic of manic episodes of 
psychiatric patients. In the absence of uni- or bipolar disorders it is currently not further 
specified in the classification systems of mental diseases. Still, its prevalence in a large study 
of patients with PD was described with 7.2% (Antonini & Cilia, 2009). A current prevalence 
of oniomania of 0.7% was reported in another study demonstrating the tentativeness of the 
current data (Voon et al., 2006b). Still, in general the prevalence of oniomania appears to be 
lower than that of pathologic gambling or hypersexuality (Ceravolo et al., 2010). Due to a 
scarcity of data specific risk factors for oniomania are not established. Most studies report 
general risk factors for developing impulse control disorders in PD with oniomania among 
them. Most significant risks for developing an oniomania are the younger age of onset of PD 
and a personal or family history of addictive behavior (Ceravolo et al., 2010; Voon et al., 
2006b). Diagnosis of oniomania in PD requires exclusion of a general hypomanic or manic 
episode. Oniomania is time-consuming and distressing and results in financial, family-
related or social problems (McElroy et al., 1994). The therapy again relies on the adjustment 
of the patients antiparkinsonian medication especially in the withdrawal from dopamine 
agonists. Additionally, the patients access to money or shopping opportunities may be 
regulated if possible.  
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3. Conclusion 
Cognitive and psychiatric consequences of Parkinson’s disease have a major impact on 
patients as well as caregivers. They affect the majority of patients with Parkinson’s disease 
to some extent. Dementia, depression and psychotic symptoms are very common traits of 
advanced parkinsonism and especially affect elderly patients. Still they remain untreated 
not infrequently. Impulse control disorders are less common in Parkinson’s disease and are 
related to the medical treatment and early onset parkinsonism. Their possibly devastating 
implications require awareness of the treating physician. Therapeutic options for the 
cognitive and psychiatric aspects of Parkinson’s disease will benefit from future research 
efforts. 
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